{"name":"Prestige Biopharma Limited","slug":"prestige-biopharma-limited","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"HD204","genericName":"HD204","slug":"hd204","indication":"Type 2 diabetes","status":"phase_3"},{"name":"HD201","genericName":"HD201","slug":"hd201","indication":"Type 2 diabetes","status":"phase_3"}]}],"pipeline":[{"name":"HD204","genericName":"HD204","slug":"hd204","phase":"phase_3","mechanism":"HD204 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"HD201","genericName":"HD201","slug":"hd201","phase":"phase_3","mechanism":"HD201 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxQYk14b3NXejlUVDJkbUN0OEhMR0pCSDFDa3pzYVZCYkxHNG9mUmJLSVZ5OUZTeVVKYUpaR3FnWmxvWGlzUWZRVHFpR3NXTHNEa2N6SkcyVGlfb3hLeGp5dFkyQzI2N1dmNXp5ZzRUbWFKWWxqQmNYMUZKUWo1dml3ZUMwQjB3cXJNMzI0ZldLOTFmS0lpb0o1X0RjazMxemg5dDQwZFk1S1lKMzVMRTRCSnN6NkNDa2xIMTNmRUtHNV8tZzh1Q3AySGo1Ym1aTnJoeVh1STVnLTBxYlROSmNHQnc0LVBCUQ?oc=5","date":"2026-03-27","type":"pipeline","source":"Barchart","summary":"Pancreatic Cancer Treatment Pipeline Shows Strong Momentum as 170+ Pharma Companies in the Race | DelveInsight - Barchart","headline":"Pancreatic Cancer Treatment Pipeline Shows Strong Momentum as 170+ Pharma Companies in the Race | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNSzN1RDdicy11MTc5LV9oTnhfQV9hOHpXWjJYWU5HSFg0VlFMQmRqcmt0OEdBTEpBMkRUbVhxUlM1VS0yWEhoOXRRMUpnN0tnMW11OWlrQU9uRlp0Y3pOX0YwMlZCUE1nSFM4bGE5OVlhdGlOZDA0NEp3UE9VOWo1d1B6UWNlcE5aSFVPTUhybk55TzZRUTNsMWdCUkhpUGJIOW9mQVdzWE5EajRTVHMxZC1fY05Ndw?oc=5","date":"2026-03-24","type":"trial","source":"The Pharma Letter","summary":"Prestige posts Phase III win for Avastin biosimilar in lung cancer - The Pharma Letter","headline":"Prestige posts Phase III win for Avastin biosimilar in lung cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAJBVV95cUxObTN3R1ZmTjJIbjNzQkFDeFBJQ250bnc0MjV5TURWamtOMkNudklJVFE2WU9waW9rdGRkdUhaQWlnNzhLemw1TVdJRnhOcm1FTGowemdtT2R4NzlpdUZZVWFXZndsbUVOaWRLWDNqVURaWVVfNjJiUWVINkkzR3N0bWdOUllXV3ZhTU1wMXRpRXp6MnF2Z2Iwb2szcXNXSVRYWGlyWXE5c1ZrYjNzLWgxZWc0U0U0YU9lTE9fT1Z4WDNpNk15STRmY05ZVExOY3RSdDVNbVJNYmY0SVNTTzNvNjdCWHRPZXlVVVdZV2hNMENzOUdMcU1MUy1YVGkzcHRLT2paTjR6anhyV1p3b0ZaTV9FOU5mamwxeFYyRzY3ZDBscEtu?oc=5","date":"2026-03-17","type":"trial","source":"StreetInsider","summary":"HER2 Positive Breast Cancer Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Domain | DelveInsight - StreetInsider","headline":"HER2 Positive Breast Cancer Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMikgJBVV95cUxOQTR0d1l3a3B2VmdFdjY0QkJVZ01rYmtPV0gtNERtMXMyN1lXdTdpOTFRRjFjREFaSENvbDByU2JUdzRVZ2Mxc3dsbU8zYm5MUElhVGl3RHkyU3NzaTZ5b3U2T1NOUGlUaE90MDNtUTB1Z2xIeWRSZ1NfTEpwU1hzcDZiZnpYX0puU1lTZmYyMDZ6YS02YnowdU1jbU1wZmh0d3pYNmpiYV9VVnpzTXRva09wdE9RUzZ1d3dWOGtVMGJwVmFaVkJndlJMM09oSWRhUWZKVUJJSW1iSXBWc0p5bm83ZlZOYmxaZXdEOG1ZZHZib2pxcUltWmFrdjJha0JhRFNKYTF3QlFjd0hEN29VTVJB?oc=5","date":"2026-02-04","type":"trial","source":"PR Newswire","summary":"Oncolytic Virus Clinical Trial Landscape Gains Momentum: 100+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - PR Newswire","headline":"Oncolytic Virus Clinical Trial Landscape Gains Momentum: 100+ Companies Lead the Charge in Pioneering New Treatments | D","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxPdDUzMG4zcDFyWGNzRVVpZm9JVld4ckVVOTltYVVDenkxejluRTFDU1lZS2dmY0NNQS1md25wRUFNeFVYS1ZTRWNMV000eC1oaUF3eXBxRTZqNTVxb01MdDN1X2hwN3NiY1pyZFJKaXd0QnRsNVZ5SGtUYXZuQ2N0QjdFWktpSV85eHFCMW9GcDhraEZYdHRKNTdOLXlsd1J6dXdxSHpzNUZraUxxdllsMWE0b2J2R3dvMFpHRmx2U2RmSDYxMXBn?oc=5","date":"2025-11-03","type":"deal","source":"selectscience.net","summary":"Teva and Prestige Biopharma enter license agreement for Tuznue commercialization in Europe - selectscience.net","headline":"Teva and Prestige Biopharma enter license agreement for Tuznue commercialization in Europe","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNQ2tJaEpFd203dVplQnRhN3ZxWGRlX0RPTlFOMVo2Rlk3VFY1bmRlSUNIZ29USUhHZTMxY3h6TWZBNWhOcTd4cUNOM3ZBRkF2cUQ4cnotbk0xSUg5S1liSHI2dVhrckVfNlpUbExQWmhhVW9WVzl2MW9DU3QwRUZ1UWFGR3dRWkxIUEZR?oc=5","date":"2025-10-31","type":"patent","source":"Insightace Analytic","summary":"Global Bevacizumab Biosimilar Market is expected to grow at an 9.0% CAGR during the forecast period for - Insightace Analytic","headline":"Global Bevacizumab Biosimilar Market is expected to grow at an 9.0% CAGR during the forecast period for","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxPN2Zmd0dwcW11Tjl4a3JmUDY2UlEzUk0yWWhoN0NWVWkwOXctekdMcVdmREp1Zm5VUjBsLS1tSzdNZUM2TGZQMThWazFiVGQzN1B0ZE5MazZReGRxWDQ4bXl6VXllTzFlMk5XZXVMc0praHByZFhsS0pPUU9oV3hGSl9WQXBHTWV4ajlDT21R?oc=5","date":"2025-10-24","type":"deal","source":"Yahoo Finance","summary":"Teva Pharmaceutical (TEVA) Enters Into a License Agreement With Prestige Biopharma for the Commercialization of Tuznue in Europe - Yahoo Finance","headline":"Teva Pharmaceutical (TEVA) Enters Into a License Agreement With Prestige Biopharma for the Commercialization of Tuznue i","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxOTFNhWXl0NDZzd05jY1BrTXZndWpURnB6akVIazFnRWY2VmxGWTFNNTBMV0sxUTJHNEZKelFLVDI1WVVGMzZyM0ZFZUpkRHl3ZkU1R0c1UUs3LUtfckotUmdvQ2hKRkRMcGVQbW9SRnduSkZaVFhHbFRsOEo2RVBiaFVzUHoweml5bzdPSk5NZUVqSHdONzg2WkVUeXQ2RlljVlVZLWFIdEVya21nYWNIMmI5d3FZLXlKU3lmQ0xPMEc2d09DbkRVRzl1cXRCd3RkN1AwS1R0QQ?oc=5","date":"2025-10-20","type":"deal","source":"Quiver Quantitative","summary":"Teva and Prestige Biopharma Enter License Agreement for Tuznue® Biosimilar Commercialization in Europe - Quiver Quantitative","headline":"Teva and Prestige Biopharma Enter License Agreement for Tuznue® Biosimilar Commercialization in Europe","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxOSHBONk5CYXpTTHJvSURmLTZxX1ZzUEZoYmdKUUJidVFHZnB4MGtuSWVHb2lTMTRVMW9jVjB3X2Z0aW5ldDZKZWNvT3ZBek5VVnpYTHRSX2MtU2J0Q1RHdC1MN09ZX2pVNm1lZjNHbTRoUTRWNnFQRDN1dWZHTjJ4S1hQWWJfVUhrQUN3V1ZTb3lMUUhHeGJhSUg3U2tIUEtVUEYw?oc=5","date":"2025-09-18","type":"pipeline","source":"European Pharmaceutical Review","summary":"CPHI Pharma Awards 2025 finalists announced - European Pharmaceutical Review","headline":"CPHI Pharma Awards 2025 finalists announced","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE01ejQ5ME1BbjRMVkxPT3ZFVVY4ZU93NjNFMEpBcmxmVlpmYkhPWUhkTlRkdjVFaHBlX2lZQ2Jsc2tnTHI4R0ZRc2FBa1BNQ2R4RmlDQ3lDWUNvWEE2MTdWU3NBYzhZYlUxRU12YUd30gFyQVVfeXFMTlRLT1Mza29sR2ozS3YxcDF6QjZvMW9KWTYxU0tadVRRRVdKajZMa1lPRHNpUkZhMm9rSXZEN1FKSWlmeEU0WTVvdEVIN1NSTjI0NC1NZnZyelpOa2RlYXpOQ0tleko1SnZnT1VkM1dkN253?oc=5","date":"2025-05-26","type":"deal","source":"koreabiomed.com","summary":"Prestige Biopharma inks European licensing deal with Teva for Herceptin biosimilar - koreabiomed.com","headline":"Prestige Biopharma inks European licensing deal with Teva for Herceptin biosimilar","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE0xSFNoak5INUhrT3RZT1JhVkpBNzZ5OU5FZGFrb184ZXFjRnV5QlBTYy1EZWZ1UFpOQWxSZ01xUnFFdVB1VEUtclRfbzNqc3RVWExnR0FmMDhNMEFQcDF1MG9qNG1zYk1LU1JSRFh3?oc=5","date":"2023-09-22","type":"deal","source":"KED Global","summary":"Prestige Biologics partners with Indian company for CDMO - KED Global","headline":"Prestige Biologics partners with Indian company for CDMO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxOZmIzRE9WOWhVLUllZU90Sk1CaEJJelItRTJLQ1RsVTZsWEpUN28xUnc0S2VEblJMYWt2eGNVVjBPQjZUc1ROTU1tUm1kZ28tSDZEbnlTZ2pnYmE2Q3lFeGJpSjhZalQyQ1ZJNWJXVVg0Rm1hQzJRX3k1TDlQU1c0LVVkU05YNGZFQS1EUWRUTlRXMHFfOGJ5ZU80Sjh1Y1E4c3puM3BwRQ?oc=5","date":"2023-07-25","type":"pipeline","source":"BioWorld News","summary":"Prestige Biopharma aims to become leading cancer drug developer - BioWorld News","headline":"Prestige Biopharma aims to become leading cancer drug developer","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}